About Conference

Diabetes Webinars 2020 | Diabetes Online Events | Diabetes Online Webinar | Scientific Webinars on Diabetes | Best Diabetes Podcasts 2020 | Diabetes Webcast | Diabetes Online Conferences | Diabetes 2020 Live Events | Diabetes Conferences 2020 With the amalgamation of peerless speakers of Diabetes 2019 Conference Series is privileged to announce its “ Diabetes Webinar ” which will be held on September 23, 2020 online. We cordially welcome all the eminent researchers, students and delegates to take part in this upcoming Diabetes conference to witness invaluable scientific discussions and contribute to future innovations in the field of Diabetes. According to WHO, about 60 million people with diabetes in the European Region. About 10.3% of men and 9.6% of women aged 25 years and over. Worldwide, high blood glucose kills about 3.4 million people annually amongst 80% of these deaths occur in low- and middle-income countries, and almost half are people aged under 70 years. WHO projects diabetes deaths will double between 2005 and 2030. The overall risk of death among people with diabetes is at least double the risk of their peers without diabetes. Reflecting this imperative, Conference Series is all set to host Diabetes webinar this year which will provide the future leadership in this key area for global health. Diabetes Webinar 2020 will focus on the latest and exciting innovations in all areas of Diabetes research which offers a unique opportunity for investigators across the globe to meet, network, and perceive new scientific innovations. The two days conference includes workshops, symposiums, special keynote sessions conducted by eminent and renowned speakers who excel in the field of Diabetes which include: Advanced Technologies for Treatment of Diabetes, Emerging Focus in Diabetes Research, Diabetes Research in Clinical Practice, Computational Biology of Diabetes, Cell Therapy for Diabetes and its Complications, Genetics of Diabetes, Diabetes Management, Transplantation for Diabetes, Endocrinology Disorders and Treatment. Young Research’s Awards at Diabetes Webinar 2020 for the Nomination: Young Researcher Forum - Outstanding Masters/Ph.D./Post Doctorate thesis work Presentation, only 25 presentations acceptable at the Diabetes Webinar 2020 young research forum. Benefits: Young Scientist Award recognition certificate and memento to the winners

Our conferences provide best Platform for your research through oral presentations.

Learn about career improvement with all the latest technologies by networking.

Young Scientists will get appropriate and timely information by this Forum.

Platform for collaboration among young researchers for better development.

Provide an opportunity for research interaction and established senior investigators across the globe in the field

Share the ideas with both eminent researchers and mentors. It’s a great privilege for young researchers to learn about the research areas for expanding their research knowledge. Diabetes Webinar 2020 provides best platform to expand your network, where you can meet scientists, authorities and CROs from around the world. It’s your time to grab the opportunity to join Diabetes Webinar 2020 for promoting your research article and to facilitate prestigious award in all categories. In this fame, we look forward for your contribution and astonishing dedication to make our Diabetes Webinar 2020 more successful.

Market Analysis “31st International Congress on Prevention of Diabetes and Complications (Diabetes Webinar 2020) which is going to be held on September 23, 2020 online. Diabetes Webinar 2020 invites all Academic Scientists, Leading Endocrinologists, Surgeons, Oncologists, Radiation Therapists, General Physicians, Dieticians, Primary Health care specialists, Internists, Pharmaceutical Industrial Delegates, talented young scientists, and student communities across the globe to attend European Diabetes conference under a single roof where networking and global partnering happens for the acceleration of future research. Today’s Market Study of Diabetes in USA | Europe | Middle East | Asia Pacific Europe: The number of people living with diabetes in Europe is expected to increase from 52 million in 2014 to 68.9 million by 2035, according to the International Diabetes Federation (IDF). Across Europe, around 1 in 11 adults is affected and this number is set to rise as the population ages. USA: Diabetes Mellitus has been growing at an exponential rate and World Health Organization (WHO) estimates that the diabetic population is likely to reach 366 million in 2030. The United States is expected to have an increase of 102 per cent in the diabetic epidemic in 2030 when compared to 2000 Middle East: The rate of diabetes in parts of the Arabian Peninsula is over twice the global average rate, and much higher than some other areas of the Middle East and North Africa (MENA). And cases of type-2 diabetes outnumber cases of type-1 diabetes by a ratio of 10:1 Asia Pacific: The Asia-Pacific Diabetes Care Devices Market has been estimated at USD 2.461 Billion in 2015 and is projected to reach USD 3.518 billion by 2020, at a CAGR of 7.41% during the forecast period from 2015 to 2020 Diabetes is one of the fastest growing health challenges of the 21st century, with the number of adults living with diabetes having more than tripled over the past 20 years. In 2000, the global estimate of adults living with diabetes was 151 million. By 2009 it had grown by 88% to 285 million. Today, we calculate that 9.3% of adults aged 20–79 years – a staggering 463 million people – are living with diabetes. A further 1.1 million children and adolescents under the age of 20 live with type 1 diabetes. A decade ago, in 2010, the global projection for diabetes in 2025 was 438 million. With over five years still to go, that prediction has already been surpassed by 25 million will be 578 million adults with diabetes by 2030, and 700 million by 2045. Type 1 diabetes is caused by an autoimmune reaction in which the body’s immune system attacks the insulin-producing beta cells of the pancreas. As a result, the body produces very little or no insulin. Type 2 diabetes is the most common type of diabetes. Initially, hyperglycaemia (high blood glucose levels) is the result of the inability of the body’s cells to respond fully to insulin, a situation termed ‘insulin resistance’. Gestational diabetes (GDM) is characterized by high blood glucose levels during pregnancy. It may occur at any time during pregnancy. Women who experience GDM face an increased risk of developing type 2 diabetes later in life. In addition, babies born to mothers with GDM also have a higher lifetime risk of obesity and developing type 2 diabetes themselves. This contributes to an intergenerational cycle of obesity and diabetes that seriously impacts the health of the entire population, and the generations to come. Impaired glucose tolerance (IGT) is a condition of raised blood glucose levels above the normal range, but below the recommended diabetes diagnostic threshold. The terms ‘prediabetes’ and ‘non-diabetic hyperglycaemia’ are sometimes used as alternatives. IGT is important because it: • Indicates a risk of developing type 2 diabetes in the future; • Denotes an already heightened risk of cardiovascular diseases; •Offers the opportunity for interventions that can lead to the prevention of type 2 diabetes. The estimated number of adults with IGT, and therefore at increased risk of developing type 2 diabetes, is 374 million. It is predicted to rise to 454 million by 2030 and to 548 million by 2045. Insulin: Launch of generic versions of insulin and extensively growing demand for novel insulin in controlling the blood sugar levels in both type 1 and type 2 diabetes ate factors anticipated to fuel the growth of insulin segment in the market during the forecast period. In march 2019 Eli Lilly (key player) and company launched Lispro, a generic version of rapid-acting Humalog insulin which shall be available in the US by making it more accessible for diabetic patients. Additionally, growing investments in research and development by many government organizations and new product launches by many key players are like to boost the diabetes drugs market growth during the forecast period. For example, in 2019 Glenmark launched an oral anti-diabetic drug Remogliflozin in India which is considered as an effective drug treating adults with type-2 diabetes mellitus. Growing urbanization and changing lifestyle habits (e.g. higher calorie intake, increasing consumption of processed foods, sedentary lifestyles) are contributory factors for the increasing prevalence of type 2 diabetes at a societal level. While global prevalence of diabetes in urban areas is 10.8%, in rural areas it is lower, at 7.2%. However, this gap is closing, with rural prevalence on the rise. Diabetes increases the risk of early death: Approximately 4.2 million adults will die as a result of diabetes and its complications in 2019. This is equivalent to one death every eight seconds. Globally, 11.3% of deaths are due to diabetes. Almost half of these deaths are in people under 60 years of age. Half of the 463 million adults living with diabetes today are unaware that they have the condition, and are therefore at high risk of developing serious diabetes related complications. Economic and social impact: Annual global health expenditure on diabetes is estimated to be at USD 760 billion under direct costs. It is projected that these direct costs will reach USD 825 billion by 2030 and USD 845 billion by 2045. The costs of treating complications account for over 50% of the direct health costs of diabetes. For example, management of diabetic ketoacidosis (DKA) is a considerable part of the cost to a country’s health system: treatment of a single DKA episode in the United Kingdom costs an estimated GBP 1,387 (around USD 1,750). Age profile of diabetes Working age (20-64) 72.0% three in four people living with diabetes (352 million people) are of working age (between 20 and 64 years old). This number is expected to increase to 417 million by 2030 and to 486 million by 2045. Older people (65+) 27.8% in 2019, the estimated number of people over 65 years of age with diabetes is 111 million. One in five adults in this age group is estimated to have diabetes. It is projected that by 2030 the number of people over 65 with diabetes will further increase to 195 million. By 2045, it will reach 276 million. Children and adolescents (0–19) 0.2% an estimated 1.1 million children and adolescents (aged under 20) have type 1 diabetes. There is some evidence that type 2 diabetes among children and adolescents is increasing in some countries. Geographical profile Age adjusted comparisons - Prevalence of diabetes in adults (20-79 years) World 2045 9.6% 2030 9.2% 2019 8.3%

Europe 2045 7.8% 2030 7.3% 2019 6.3% South & Central America 2045 9.9% 2030 9.5% 2019 8.5%

Middle East & North Africa 2045 13.9% 2030 13.3% 2019 12.2%

North America & Caribbean 2045 13.0% 2030 12.3% 2019 11.1%

Africa 2045 5.2% 2030 5.1% 2019 4.7%

South-East Asia 2045 12.6% 2030 12.2% 2019 11.3%

Western Pacific 2045 12.8% 2030 12.4% 2019 11.4%

Countries with the highest numbers of people with diabetes (2019) In 2019, the countries with the largest numbers of adults with diabetes are China, India and the United States of America, and are anticipated to remain so until 2030. It is projected that the number of people with diabetes in Pakistan will exceed that in the United States of America by 2045, moving the country to third place. Rank Country No. of people with diabetes (millions) 1 China 116.4 2 India 77.0 3 USA 77.0 4 Pakistan 19.4 5 Brazil 16.8 6 Mexico 12.8 7 Indonesia 10.7 8 Germany 9.5 9 Egypt 8.9 10 Bangladesh 8.4

Low- and middle-income countries: The highest prevalence of diabetes in adults occurs in high-income countries, with an estimated 10.4% of the population having diabetes. The diabetes prevalence is 4% in low-income countries, and 9.5% in middle-income countries. Improved education at the population-level, strong health systems, and effective policy frameworks are key to adequately address the primary risk factors of type 2 diabetes (such as poor eating habits, obesity and inadequate physical activity) and the high numbers of people living with undiagnosed diabetes Societies Associated with Diabetes Research: Spanish Diabetes Society (Spain)

FAND - Italian Association of Diabetics

Italian Association for the Defence of the Interests of Diabetics

Association of Diabetes

Association National Italian Diabetic Athletes

Italian Society of Diabetology

International Diabetes Federation- Italy

Primary Care Diabetes Society

Australian Diabetes Society

Emirates Diabetes Society

Society for Biomedical Diabetes Research

Immunology of Diabetes Society

American Association of Diabetes Educators

American Diabetes Association

The Asian Association for the Study of Diabetes

International Association of the Diabetes and Pregnancy Study Groups

Diabetes Association of Nigeria

Association of Children's Diabetes Clinicians

Canadian Diabetes Association

Diabetes Australia

Austrian Diabetes Association

Flemish Diabetes Association (Belgium

Association of Juvenile Diabetes (Brazil

Canadian Diabetes Association

Juvenile Diabetes Foundation of Chile

Diabetological Colombian Federation

Croatian Diabetes Association

Union of Diabetics of Czech Republic

Estonian Diabetes Association

Finnish Diabetes Association

French Diabetics Association

German Diabetes Union

Hellenic Diabetes Association (Greece)

Hong Kong Diabetes Federation

Icelandic Diabetic Association

Diabetic Association of India

Diabetes Federation of Ireland

The Diabetes Association (Italy)

Japan Diabetes Society

Korean Diabetes Association

Lithuanian Diabetes Association

Luxembourg Diabetes Association

Maltese Diabetes Association (Malta)

Mexican Diabetes Federation

Netherlands Diabetes Association

Diabetes New Zealand

Norwegian Diabetes Association

Diabetes Philippines

Polish Diabetes Association

Diabetic Association of Portugal

Diabetic Society of Singapore

Diabetes South Africa

Swedish Diabetes Association

Swiss Diabetes Society

Diabetes UK